Lan Kang

Lan Kang is currently President & Chief Executive Officer at Azkarra Therapeutics, Inc. since 2025.
Serving as Chairman at Pramerica Fosun Life Insurance Co., Ltd. since 2017.
Senior Managing Director at Shanghai Kangshiqiao Business Consulting Co. Ltd. since 2020.
Managing Director at C Bridge Value Creation Ltd. Former roles include Chairman of the Board at AmeriTrust Group, Inc. from 2015 to 2018.
Vice Chairman Of The Board at Fidelidade Companhia de Seguros SA from 2017 to 2018.
Executive Director & Chief Human Resources Officer at Fosun International Ltd. from 2017 to 2018.
Non-Executive Director at Shanghai Fosun Pharmaceutical (Group) Co., Ltd. from 2013 to 2018.
Director at Peak Reinsurance Co., Ltd. from 2014 to 2018.
Independent Director at Avantor, Inc. from 2021 to 2026.
Non-Executive Director at Everest Medicines Ltd. from 2020 to 2024.
Director at I-MAB Biopharma Co., Ltd. from 2021 to 2024.
Senior MD & Head-Portfolio Management at CBC Group, Inc. from 2020 to 2024.
Senior Advisor at Shanghai Henlius Biotech, Inc. from 2019 to 2020.
Senior Client Partner at Korn from 2007 to 2010.
Engagement Manager at McKinsey & Co., Inc. from 2002 to 2007.
Project Manager at Nanjing Jiangbei New Area Industrial Investment Group Co. Ltd. from 1991 to 1993.
Also held various director and vice president roles at Fosun United Health Insurance Co. Ltd., Fosun Pharma Group Co. Ltd., Ironshore, Inc., and Shanghai Fosun High Technology (Group) Co., Ltd. Education includes a graduate degree from Tulane University (1995), an undergraduate degree from Zhejiang University (1991), and an MBA from The Wharton School of the University of Pennsylvania (2002).